artenimol has been researched along with Cancer of Pancreas in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Gao, W; Huang, L; Liu, X; Sheng, W; Wang, F; Wang, Y; Ye, J; Yu, H; Zhou, H | 1 |
| Du, J; Fang, L; Hu, W; Jing, Q; Li, H; Li, Y; Ren, X; Tong, X; Wang, L; Wang, X; Wang, Y; Yang, C; Zhou, C; Zhou, Y | 1 |
| Li, Y; Li, YW; Lv, SJ; Xu, N; Zhang, H; Zhang, W; Zhu, WH | 1 |
| Chen, FX; Chen, L; Fei, SJ; Ji, HC; Lü, XT; Qian, H; Sun, LQ; Xu, WR; Zhang, J; Zhou, ZH | 1 |
| Han, B; Jia, G; Kong, R; Li, YH; Ma, ZB; Pan, SH; Sun, B; Wang, YW | 1 |
| Chen, H; Kong, R; Li, Y; Pan, S; Sun, B; Wang, Y; Xue, D | 1 |
| Chen, H; Jiang, H; Pan, S; Sun, B; Sun, X | 1 |
| Bai, X; Chen, H; Gao, Y; Pan, S; Sun, B; Wang, S; Xue, D | 1 |
| Chen, H; Jiang, HC; Li, J; Meng, QH; Pan, SH; Sun, B; Xue, DB | 1 |
| Bai, XW; Chen, H; Gao, Y; Jiang, HC; Kong, R; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Bai, XW; Chen, H; Jiang, HC; Kong, R; Li, J; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Bai, XW; Chen, H; Cheng, ZX; Gao, Y; Jiang, HC; Kong, R; Pan, SH; Sun, B; Wang, SJ; Xue, DB; Zhou, HX | 1 |
| Aung, W; Furukawa, T; Saga, T; Sogawa, C | 1 |
| Cheng, ZX; Dong, DL; Gao, Y; Jia, G; Jiang, HC; Kong, R; Mu, M; Pan, SH; Sun, B; Wang, SJ; Wang, YW | 1 |
14 other study(ies) available for artenimol and Cancer of Pancreas
| Article | Year |
|---|---|
Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy of Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Mice; Nanoparticles; Oxidation-Reduction; Pancreatic Neoplasms | 2023 |
DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Ferroptosis; Humans; Iron; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasm Invasiveness; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
[Dihydroartemisinin inhibits proliferation of pancreatic cancer JF-305 cells by regulating expression of apoptosis related proteins and production of reactive oxygen species].
Topics: Apoptosis; Artemisinins; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Proliferation; Cytochromes c; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2017 |
Enhancement effect of dihydroartemisinin on human γδ T cell proliferation and killing pancreatic cancer cells.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Artemisinins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Granzymes; Humans; Interferon-gamma; Lysosomal-Associated Membrane Protein 1; Pancreatic Neoplasms; Perforin; T-Lymphocyte Subsets; T-Lymphocytes; Young Adult | 2013 |
The activation of c-Jun NH₂-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Artemisinins; Autophagy; Beclin-1; Caspase 3; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Reactive Oxygen Species | 2014 |
Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Artemisinins; Cell Line, Tumor; Cell Proliferation; Female; Gene Regulatory Networks; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Messenger; Transfection | 2016 |
Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artemisinins; bcl-2-Associated X Protein; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2009 |
Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.
Topics: Antineoplastic Agents; Artemisinins; Blotting, Western; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Interphase; NF-kappa B; Pancreatic Neoplasms; Translocation, Genetic | 2010 |
[Study on anticancer effect of dihydroartemisinin on pancreatic cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2009 |
Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Growth Processes; Cell Survival; Deoxycytidine; DNA, Neoplasm; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
[Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway.
Topics: Angiogenesis Inhibitors; Animals; Artemisinins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endothelial Cells; Humans; Male; Mice; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms | 2011 |
Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging.
Topics: Animals; Antimalarials; Apoptosis; Artemisinins; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Diagnostic Imaging; Disease Models, Animal; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2012 |